Clinical Trial Update: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating tocilizumab for Juvenile Idiopathic Arthritis associated uveitis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis-associated Uveitis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Eric B. Suhler | Conditions: Juvenile Idiopathic Arthritis Associated Uveitis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-11-27